News & Updates
Filter by Specialty:
Real-world study favours ritonavir-based regimens for hospitalized COVID-19 patients
In a real-world analysis evaluating four oral antiviral agents for the treatment of COVID-19, two ritonavir-based regimens fared better than molnupiravir and azvudine in reducing hospital stay among patients hospitalized for mild or moderate disease.
Real-world study favours ritonavir-based regimens for hospitalized COVID-19 patients
21 Oct 2024
1L nab-paclitaxel + S-1 extends PFS and OS vs nab-paclitaxel + gemcitabine in Chinese patients with advanced pancreatic cancer
A phase II trial demonstrated significantly longer progression-free survival (PFS) and overall survival (OS) in Chinese patients with advanced pancreatic cancer (APC) who received first-line treatment with nab-paclitaxel plus S-1 (AS) vs nab-paclitaxel plus gemcitabine (AG).
1L nab-paclitaxel + S-1 extends PFS and OS vs nab-paclitaxel + gemcitabine in Chinese patients with advanced pancreatic cancer
21 Oct 2024
Prior local therapy enhances apalutamide’s effect on metastasis-free survival
A secondary post hoc analysis of the phase III SPARTAN trial shows that patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who received prior prostate-directed local therapy (LT) had longer metastasis-free survival (MFS) when treated with apalutamide vs those without prior LT.
Prior local therapy enhances apalutamide’s effect on metastasis-free survival
21 Oct 2024
Second-line tislelizumab + anlotinib + chemo shows potential to improve ES-SCLC survival
A treatment regimen combining tislelizumab, anlotinib, and two cycles of irinotecan in the second-line setting demonstrates favourable efficacy and safety in patients with extensive-stage small cell lung cancer (ES-SCLC), according to the results of the single-arm phase II ESTAIL study.